Search research articles
Contact Us
Filters
Showing results (51-60 of 77) with videos related to
Page
of 8
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
January 1, 1992
A reappraisal of the role of prophylactic cranial irradiation in limited small cell lung cancer
M Rosenstein, J Armstrong, M Kris, et al.
Archives of Otolaryngology--Head & Neck Surgery
|
January 1, 1994
Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer
D G Pfister, D Bajorin, R Motzer, et al.
Cancer
|
March 26, 1999
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
P M Dodd, J A McCaffrey, M Mazumdar, et al.
Cancer Investigation
|
October 19, 2000
Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer
P M Dodd, J A McCaffrey, M Mazumdar, et al.
Investigational New Drugs
|
February 1, 1993
A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer
D G Pfister, D Bajorin, R J Motzer, et al.
Progress in Clinical and Biological Research
|
January 1, 1990
M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation
H Scher, H Herr, C Sternberg, et al.
British Journal of Urology
|
September 1, 1989
Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen
H Scher, H Herr, C Sternberg, et al.
European Journal of Cancer & Clinical Oncology
|
April 1, 1989
Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program
C N Sternberg, A Yagoda, H Scher, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
July 5, 2006
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib
M D Stubblefield, S Slovin, B MacGregor-Cortelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 1998
Expression of cyclin D1, but not cyclins E and A, is related to progression in bilharzial bladder cancer
I Osman, H Scher, Z F Zhang, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 77) with videos related to
Sort By:
Page
of 8
International Journal of Radiation Oncology, Biology, Physics
|
January 1, 1992
A reappraisal of the role of prophylactic cranial irradiation in limited small cell lung cancer
M Rosenstein, J Armstrong, M Kris, et al.
Archives of Otolaryngology--Head & Neck Surgery
|
January 1, 1994
Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer
D G Pfister, D Bajorin, R Motzer, et al.
Cancer
|
March 26, 1999
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
P M Dodd, J A McCaffrey, M Mazumdar, et al.
Cancer Investigation
|
October 19, 2000
Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer
P M Dodd, J A McCaffrey, M Mazumdar, et al.
Investigational New Drugs
|
February 1, 1993
A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer
D G Pfister, D Bajorin, R J Motzer, et al.
Progress in Clinical and Biological Research
|
January 1, 1990
M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation
H Scher, H Herr, C Sternberg, et al.
British Journal of Urology
|
September 1, 1989
Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen
H Scher, H Herr, C Sternberg, et al.
European Journal of Cancer & Clinical Oncology
|
April 1, 1989
Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program
C N Sternberg, A Yagoda, H Scher, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
July 5, 2006
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib
M D Stubblefield, S Slovin, B MacGregor-Cortelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 1998
Expression of cyclin D1, but not cyclins E and A, is related to progression in bilharzial bladder cancer
I Osman, H Scher, Z F Zhang, et al.
Page
of 8